Table 1 Basic data of included studies
First author | Year | Country | Evidence level | Interventions | Sample (shoulder) | Follow-up (months) | Study design | Outcome | Nos |
|---|---|---|---|---|---|---|---|---|---|
Mohamed | 2018 | Egypt | III | MMA versus SB | 21/25 | 49 | RCT | Constant; ASES | – |
Michael E | 2018 | Greece | II | SR versus SB | 34/32 | 46 | RCS | Constant; healing rate | 7 |
Christian | 2012 | Germany | III | MMA versus SB | 20/20 | 16 | RCS | Constant; healing rate | 8 |
Kwang | 2018 | Korea | III | MMA versus SB | 39/37 | 35 | RCS | Constant; ASES; healing rate | 8 |
William | 2010 | USA | III | SR versus SB | 78/54 | 24 | PCS | ASES; healing rate | 9 |
Atsushi | 2017 | Japan | II | TO versus SB | 11/10 | 6 | RCT | Constant | – |
Teruhisa | 2011 | Japan | III | SR versus DR versus SB | 65/23/107 | 24 | RCS | ASES; healing rate | 9 |
Cosimo | 2013 | Italy | III | SR versus DR | 20/20 | 40 | RCS | Constant; healing rate | 8 |
Frank | 2014 | USA | III | SR versus DR versus SB | 20/21/22 | 24 | RCS | Constant; ASES; healing rate | 9 |
Ignacio | 2012 | Spain | I | SR versus DR | 80/80 | 24 | RCT | Constant; ASES; healing rate | - |
Gary M | 2013 | USA | I | SR versus SB | 43/47 | 10 | RCT | Healing rate | – |
Ji-Sang | 2019 | Korea | III | SR versus SB | 31/25 | 24 | RCS | Constant; ASES; healing rate | 7 |
Burks | 2009 | Australia | I | SR versus DR | 20/20 | 12 | RCT | ASES | – |
Ma | 2011 | China | II | SR versus DR | 27/20 | 24 | RCT | Constant; ASES; healing rate | – |
Charousset | 2007 | France | II | SR versus DR | 35/31 | 28 | RCS | ASES; healing rate | 6 |
Park | 2008 | Korea | II | SR versus DR | 40/38 | 24 | RCS | Constant; healing rate | 8 |
Franceschi | 2007 | Italy | I | SR versus DR | 30/30 | 24 | RCT | Constant; ASES | – |
Sugaya | 2005 | Japan | III | SR versus DR | 39/41 | 35 | RCS | Healing rate | 8 |
Kyoung | 2011 | Korea | I | SR versus DR | 31/31 | 24 | RCT | ASES; healing rate | – |
Andrea | 2009 | Italy | I | SR versus DR | 40/40 | 24 | RCT | Constant; ASES; healing rate | – |
Nuri | 2009 | Turkey | II | SR versus DR | 34/34 | 24 | RCT | Constant | – |
Lapner | 2012 | Canada | I | SR versus DR | 39/34 | 24 | RCT | Constant | – |
Francesco | 2016 | Italy | I | SR versus DR | 25/25 | 24 | RCT | Constant; ASES; healing rate | – |
Eduard | 2009 | Switzerland | III | SR versus DR | 32/33 | 25 | RCS | Healing rate | 8 |
Manuel | 2020 | Spain | II | SR versus SB | 25/25 | 33 | PCS | Constant | 9 |
Randelli P | 2017 | California | I | TO versus SR | 34/35 | 15 | RCT | Constant; ASES; healing rate | – |
LuĂs Filipe | 2018 | Brazil | III | SR versus DR | 29/27 | 38 | RCS | Constant; ASES; healing rate | 8 |
Jeung | 2017 | Korea | III | SR versus SB | 190/225 | 53 | RCS | ASES | 7 |
Jong-Hun | 2010 | Korea | III | SR versus DR | 22/25 | 22 | RCS | Constant; ASES; healing rate | 8 |
Roshan | 2017 | India | II | SR versus DR | 28/28 | 6 | RCT | ASES; healing rate | – |
Junji | 2015 | Japan | III | SR versus SB | 25/36 | 81 | RCS | Healing rate | 7 |
Raffaele | 2018 | Italy | II | TO versus SR | 54/42 | 24 | RCS | Constant; ASES; healing rate | 9 |
Robert Z | 2018 | USA | III | SR versus SB | 22/25 | 12 | RCS | ASES; healing rate | 7 |
Francisco | 2006 | Spain | I | SR versus DR | 50/50 | 26 | RCT | Healing rate | – |